Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Kindred Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KIN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: KIN underperformed the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: KIN underperformed the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Kindred Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StIs Kindred Biosciences (NASDAQ:KIN) A Risky Investment?
4 weeks ago | Simply Wall StKindred Biosciences'(NASDAQ:KIN) Share Price Is Down 44% Over The Past Three Years.
1 month ago | Simply Wall StHow Much Is Kindred Biosciences, Inc. (NASDAQ:KIN) CEO Getting Paid?
Is Kindred Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KIN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KIN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KIN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: KIN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KIN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KIN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.4x).
How is Kindred Biosciences forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KIN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KIN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KIN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KIN's revenue (34.6% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: KIN's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KIN's Return on Equity is forecast to be high in 3 years time
How has Kindred Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KIN is currently unprofitable.
Growing Profit Margin: KIN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KIN is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.
Accelerating Growth: Unable to compare KIN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KIN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: KIN has a negative Return on Equity (-34.26%), as it is currently unprofitable.
How is Kindred Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: KIN's short term assets ($72.8M) exceed its short term liabilities ($6.9M).
Long Term Liabilities: KIN's short term assets ($72.8M) exceed its long term liabilities ($22.2M).
Debt to Equity History and Analysis
Debt Level: KIN's debt to equity ratio (22.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if KIN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KIN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: KIN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 23.3% each year
What is Kindred Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KIN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KIN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KIN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KIN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KIN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Richard Chin (53 yo)
Dr. Richard Chin, M.D. serves as President at Kindred Biosciences, Inc. since July 31, 2020. Dr. Chin is a Co-Founder of Kindred Biosciences, Inc. and has been its Chief Executive Officer since October 201 ...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD3.59M) is above average for companies of similar size in the US market ($USD1.23M).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
|Co-Founder & Director||2yrs||US$1.46m||0.37% |
|CFO & Secretary||3.25yrs||US$987.87k||0.11% |
|Chief Scientific Officer||2.75yrs||US$982.70k||0.094% |
|Chief of Staff||no data||no data||no data|
Experienced Management: KIN's management team is seasoned and experienced (5.6 years average tenure).
|Co-Founder & Director||2yrs||US$1.46m||0.37% |
|Independent Director||4.5yrs||US$266.70k||0% |
|Independent Director||2.5yrs||US$253.75k||0.43% |
|Independent Director||2.5yrs||US$251.16k||0% |
|Independent Director||7.67yrs||US$258.93k||0% |
|Independent Director||6.92yrs||US$258.93k||0.063% |
Experienced Board: KIN's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Kindred Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Kindred Biosciences, Inc.
- Ticker: KIN
- Exchange: NasdaqCM
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$158.261m
- Shares outstanding: 39.37m
- Website: https://www.kindredbio.com
Number of Employees
- Kindred Biosciences, Inc.
- 1555 Bayshore Highway
- Suite 200
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|KIN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 2013|
|17K||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2013|
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic clas ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 23:42|
|End of Day Share Price||2020/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.